Monte Rosa Therapeutics, Inc.
GLUE
$15.50
-$0.34-2.15%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -43.40M | -44.50M | -46.14M | -27.08M | -12.30M |
| Total Depreciation and Amortization | 2.62M | 2.67M | 2.76M | 2.73M | 2.74M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.29M | 4.32M | 3.72M | 3.26M | 3.54M |
| Change in Net Operating Assets | -7.63M | 141.00K | -3.36M | 121.52M | -28.71M |
| Cash from Operations | -44.11M | -37.37M | -43.01M | 100.43M | -34.72M |
| Capital Expenditure | -4.72M | -1.87M | -767.00K | -651.00K | -1.70M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -24.14M | -259.13M | -64.30M | 38.79M | 27.02M |
| Cash from Investing | -28.86M | -261.00M | -65.07M | 38.14M | 25.32M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 3.21M | 349.52M | 29.98M | 348.00K | 365.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -21.19M | -357.00K | -- | -- |
| Cash from Financing | 3.21M | 328.34M | 29.62M | 348.00K | 365.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -69.76M | 29.97M | -78.46M | 138.91M | -9.03M |